Johnson & Johnson (NYSE:JNJ) Stock Falls 1.1% Following Insider Selling

Johnson & Johnson (NYSE:JNJ – Get Free Report)’s stock price was down 1.1% during mid-day trading on Monday after an insider sold shares in the company. The stock traded as low as $282.33 and last traded at $282.6220. 7,837,458 shares were traded during trading, a decline of 1% from the average daily volume of 7,952,161 shares. The stock had previously closed at $285.75.

Specifically, EVP Elizabeth Forminard sold 13,072 shares of the stock in a transaction dated Thursday, November 12th. The stock was sold at an average price of $284.39, for a total transaction of $3,717,546.08. Following the transaction, the executive vice president directly owned 16,994 shares in the company, valued at approximately $4,832,923.66. This represents a 43.48% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on JNJ shares. Citigroup lifted their price target on Johnson & Johnson from $298.00 to $303.00 and gave the stock a “buy” rating in a research note on Monday, October 5th. Morgan Stanley dropped their price objective on Johnson & Johnson from $294.00 to $292.00 and set an “overweight” rating for the company in a research note on Thursday, October 15th. Erste Group Bank lowered Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Wednesday, October 21st. Guggenheim restated a “buy” rating and issued a $287.00 target price on shares of Johnson & Johnson in a report on Wednesday, October 7th. Finally, Raymond James Financial set a $280.00 price target on shares of Johnson & Johnson in a report on Monday, August 3rd. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $275.92.

Get Our Latest Analysis on Johnson & Johnson

Key Stories Impacting Johnson & Johnson

Here are a few of the latest stories about JNJ:

  • Positive Sentiment: J&J agreed to acquire Ollin Biosciences for $2.2 billion upfront, with up to about $1.1 billion in additional milestone payments. Ollin’s OLN324 is being developed for serious retinal diseases, including wet age-related macular degeneration and diabetic macular edema. J&J to acquire Ollin Biosciences
  • Neutral Sentiment: Ollin’s treatments remain investigational and require successful late-stage trials and regulatory approval. The deal could expand J&J’s eye-care portfolio, but returns depend on clinical and commercial execution.
  • Negative Sentiment: Reports show ETFs were net sellers of $72.5 million in J&J shares on Thursday, while EVP Elizabeth Forminard sold 13,072 shares. These transactions may add pressure, although neither alone indicates a change in the company’s outlook. ETFs are net sellers of J&J J&J EVP sells shares

Johnson & Johnson Trading Down 1.1%

The stock’s fifty day simple moving average is $266.97 and its two-hundred day simple moving average is $249.85. The firm has a market cap of $680.36 billion, a PE ratio of 42.82, a PEG ratio of 2.82 and a beta of 0.22. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last released its earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.53 by $0.06. The firm had revenue of $25.40 billion during the quarter, compared to analyst estimates of $25.38 billion. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The business’s revenue was up 5.9% on a year-over-year basis. During the same period last year, the business earned $2.80 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. On average, sell-side analysts forecast that Johnson & Johnson will post 11.12 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be issued a $1.34 dividend. This represents a $5.36 annualized dividend and a yield of 1.9%. The ex-dividend date of this dividend is Tuesday, November 24th. Johnson & Johnson’s payout ratio is 81.21%.

Institutional Investors Weigh In On Johnson & Johnson

Institutional investors have recently modified their holdings of the stock. Wellington Management Group LLP lifted its stake in shares of Johnson & Johnson by 12.5% during the 2nd quarter. Wellington Management Group LLP now owns 22,588,696 shares of the company’s stock worth $5,736,851,000 after acquiring an additional 2,513,321 shares during the last quarter. Deutsche Bank AG grew its position in Johnson & Johnson by 8.5% in the 2nd quarter. Deutsche Bank AG now owns 15,661,323 shares of the company’s stock valued at $3,977,506,000 after acquiring an additional 1,225,676 shares during the last quarter. Fisher Asset Management LLC increased its stake in Johnson & Johnson by 11.5% in the third quarter. Fisher Asset Management LLC now owns 14,837,126 shares of the company’s stock worth $3,927,981,000 after purchasing an additional 1,530,070 shares during the period. Amundi increased its stake in Johnson & Johnson by 17.5% in the first quarter. Amundi now owns 13,406,820 shares of the company’s stock worth $3,277,163,000 after purchasing an additional 2,001,139 shares during the period. Finally, Janus Henderson Group PLC increased its stake in Johnson & Johnson by 1.9% in the first quarter. Janus Henderson Group PLC now owns 7,872,478 shares of the company’s stock worth $1,924,323,000 after purchasing an additional 148,497 shares during the period. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Company Profile

(Get Free Report)

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.

Featured Stories

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.